Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2022 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $90000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 89.77% year-over-year to $90000.0, compared with a TTM value of $90000.0 through Dec 2025, down 89.77%, and an annual FY2025 reading of $90000.0, down 89.77% over the prior year.
  • Other Non-Current Liabilities was $90000.0 for Q4 2025 at Agios Pharmaceuticals, roughly flat from $90000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.3 million in Q4 2022 and bottomed at $90000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 4 years is $1.0 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities grew 9.57% in 2023, then crashed 92.21% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $3.3 million in 2022, then crashed by 64.75% to $1.2 million in 2023, then decreased by 23.88% to $880000.0 in 2024, then plummeted by 89.77% to $90000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AGIO at $90000.0 in Q4 2025, $90000.0 in Q3 2025, and $101000.0 in Q2 2025.